Olympus (OTCMKTS:OCPNY – Get Free Report) and Nexalin Technology (NASDAQ:NXL – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.
Analyst Ratings
This is a breakdown of current ratings and price targets for Olympus and Nexalin Technology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Olympus | 0 | 0 | 1 | 0 | 3.00 |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
Insider and Institutional Ownership
0.0% of Olympus shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Olympus has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.08, suggesting that its share price is 308% more volatile than the S&P 500.
Profitability
This table compares Olympus and Nexalin Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Olympus | 13.80% | 24.30% | 9.30% |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
Valuation & Earnings
This table compares Olympus and Nexalin Technology”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Olympus | $7.74 billion | 2.99 | $1.03 billion | $0.82 | 21.95 |
| Nexalin Technology | $300,000.00 | 4.22 | -$8.22 million | ($14.41) | -0.12 |
Olympus has higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.
Summary
Olympus beats Nexalin Technology on 9 of the 13 factors compared between the two stocks.
About Olympus
Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.
